Urologix® is founded to develop manufacture and market medical devices for the treatment of urological disorders
Urologix’ first product, the Targis® Cooled TUMT System, is approved by the FDA as a safe, durable, minimally invasive urological treatment alternative to drugs and surgery for the treatment of BPH
Cruise software update including automated urethral feedback introduced
Urologix purchases the Prostatron® Cooled TUMT System
Cruise II software update with enhanced rectal temperature feedback preventing unnecessary system shut downs introduced
Shorter treatment time (28.5 minutes) approved
Targis Microwave Catheter [Short] introduced
Targis Microwave Catheter [Long] introduced
Cooled ThermoCath® (CTC) [Standard] Microwave Catheter receives FDA approval
Rectal Thermal Unit Plus offered
Urologix acquires three regional mobile BPH treatment service providers and launched its Urologix Mobile™ Service
Cooled ThermoCath (CTC) [Long] Microwave Catheter receives FDA approval
The CoolWave® Control Unit enabling urologists to further customize benign prostatic hyperplasia treatment (BPH treatment) options for individual patients, is approved by the FDA and released to the marketplace
Developed software upgrade for Targis System
Began CTC Advance® Microwave Catheter* development
CTC Advance® Microwave Catheter receives FDA approval
5 Year results for Cooled ThermoTherapy™ presented at AUA, Continuing Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH
5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Abstract 2122, presented at the 2009 AUA Annual Meeting in Chicago, IL
Effects of Urethral Temperature on Patient Outcomes for BPH with Cooled High Energy TUMT, Abstract 1944, presented at the 2009 AUA Annual Meeting in Chicago, IL
CTC Advance® Short Microwave Catheter released to the market to complete CTC Advance Microwave Catheter product line
Urologix selected to present at the Geriatric Urological Society Annual Meeting; ‘Sexual Function after Cooled High Energy Transurethral Thermotherapy: Results of Patient Clinical Data up to 5 Years Post-Treatment’ and ‘Intra-Prostatic Temperatures and Necrosis during High Energy Cooled Microwave Treatment’
5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH published in the May issue of the Journal of Urology. Authors include L. Mynderse, C. Roehrborn, A. Partin, G. Preminger, and E. Cote.
Acquires worldwide exclusive license to Prostiva® RF Therapy system Sep 6, 2011.
Urologix becomes the licensed manufacturer for Prostiva® RF Therapy thereby acquiring manufacturing and regulatory responsibility for the product.
Urologix joins sister companies Laser Peripherals and Clarus Medical when it was purchased in May by Scott Sundet. Continuing the focus with Urologist to offer the appropriate BPH therapies to meet patient and Urologist needs in an affordable program.